LOGO
LOGO

DERM Stock On The Rise: Worth Watching As Emrosi Adoption Expands

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
derm 08122025 lt

Journey Medical Corp. (DERM), a commercial-stage pharmaceutical company headquartered in Scottsdale, Arizona, is drawing attention with steady gains in recent trading. The company specializes in dermatological treatments, offering a portfolio that includes Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm, Targadox, Emrosi, and Luxamend. Its focus on both established therapies and new product launches positions it as an active player in the dermatology market.

Clinical Validation and Payer Expansion for Emrosi

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.